Printer Friendly

Multidrug-resistant Acinetobacter baumannii.

To the Editor: In the January 2007 issue of Emerging Infectious Diseases, Sunenshine et al. (1) described their finding of an independent association between patients with multidrug-resistant (MDR) Acinetobacter infection and increased hospital and intensive care unit (ICU) length of stay compared with that for patients with antimicrobial drug-susceptible Acinetobacter infection. The authors did not, however, find a statistically significant difference in mortality rates between the 2 groups of patients.

Acinetobacter infections frequently occur in severely ill ICU patients with other chronic illnesses or prolonged hospitalizations. We analyzed data for 27 neutropenic cancer patients with A. baumannii-associated bacteremia (15 with MDR and 12 with drug-susceptible A. baumannii infections) but no other chronic illness. We considered A. baumannii strains to be MDR if they were resistant to amikacin, meropenem, and ciprofloxacin. Univariate analysis (Epi Info 2000; Centers for Disease Control and Prevention, Atlanta, GA, USA) showed that most of the bacteremic episodes were associated with certain risk factors, such as catheter insertion, neutropenia, acute leukemia, and previous prophylactic treatment with quinolones or therapeutic treatment with cephalosporins or carbapenems (meropenem or imipenem) (Table).

Septic shock developed in 4 (14.8%) of the 27 neutropenic patients with A. baumannii-associated bacteremia, and 2 (7.4%) of the 27 died (Table). However, we did not find a statistically significant association between death among patients with bacteremia caused by MDR A. baumanni (1 death) compared with death among those with bacteremia caused by A. baumannii strains susceptible to the carbapenems, ciprofloxacin, and amikacin (1 death) (Table). This finding is similar to that described by Sunenshine et al. (1) in the general ICU population and in neutropenic cancer patients with bacteremia; however, multivariate analysis was not conducted to control for severity of illness and coexisting illness. In conclusion, neutropenic cancer patients with bacteremia due to MDR A. baumannii infection do not appear to be at increased risk for death compared with patients with bacteremia due to antimicrobial drug-susceptible A. baumannii.

This work was supported by grant 06/07/VEGA of the Ministry of Education of Slovak Republic and approved by the Ethics Committee of St Elizabeth Cancer Institute in Bratislava.


(1.) Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13: 97-103.

Vladimir Krcmery * and Erich Kalavsky ([dagger])

* St Elizabeth School of Health and Social Sciences, Bratislava, SIovakia; and ([dagger]) Trnava University, Trnava, SIovakia

Address for correspondence: Vladimir Krcmery, St Elizabeth School of Health and Social Sciences, Department of Ontology, Heydukova 10, 812 50 Bratislava, Slovakia; email: vladimir.
Table. Risk factors and outcome for 27 neutropenic cancer patients
with bacteremia due to multidrug-resistant (MDR) or drug-susceptible
Acinetobacter baumannii infection

 Patients with
 All patients, A. baumannii,
 no. (%) no. (%) *
Characteristic (N = 27) (n = 12, 44%)

Risk for bacteremia
 Central venous catheter 19 (70.4) 9 (75.0)
 Acute leukemia 11 (40.7) 6 (50.0)
 Previous prophylaxis with
 quinolones 14 (51.9) 8 (66.7)
 Previous therapeutic
 treatment with 15 (55.6) 8 (66.7)
 Previous therapeutic
 treatment with carbapenems 8 (29.6) 4 (33.3)
 Septic shock 4 (14.8) 2 (16.7)
 Death 2 (7.4) 1 (8.3)

 Patients with
 A. baumannii,
 no. (%) *
Characteristic (n = 15, 56%)

Risk for bacteremia
 Central venous catheter 10 (66.7)
 Acute leukemia 5 (33.3)
 Previous prophylaxis with
 quinolones 6 (40.0)
 Previous therapeutic
 treatment with 7 (46.7)
 Previous therapeutic
 treatment with carbapenems 4 (26.7)
 Septic shock 2 (13.3)
 Death 1 (6.7)

* Insignificant difference between patients with drug-susceptible
infection and those with MDR infection (p<0.05 by univariate
analysis). *
COPYRIGHT 2007 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:LETTERS
Author:Kalavsky, Erich
Publication:Emerging Infectious Diseases
Article Type:Letter to the editor
Date:Jun 1, 2007
Previous Article:Wound botulism in injection drug users.
Next Article:Serogroup X in meningococcal disease, Western Kenya.

Related Articles
As NCLB reauthorization looms, many debate the logistics.
Comprehension strategies kit: Sundance Publishing.
Social studies: mastering content and skills.
The top 10 advantages of software as a service for the call center.
Program Manager competencies.
Exposing the Sins of Memory.
Distinguishing between Experiment and Demo.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters